Search
Displaying 601–610 of 1063 results
-
A Gene Therapy Primer for People with Inherited Retinal Diseases
Research NewsEverything patients and families want to know about gene therapy…and a little bit more
-
Foundation News
This exclusive conversation and acoustic performance by Sam and Casey Harris of X Ambassadors on August 20, will raise awareness and funds to find treatments and cures for blinding diseases.
-
Foundation Fighting Blindness and the Retinal Degeneration Fund
In the PressIn 2018, the Foundation Fighting Blindness launched a venture philanthropy investment arm called the Retinal Degeneration (RD) Fund to help companies and researchers advance promising treatments for inherited retinal diseases into and through early-stage human studies. Currently, the RD Fund has allocated about 75% of its $72 million fund to eight investments.
-
4D Molecular Therapeutics Launches Phase 1 Clinical Trial for Choroideremia Gene Therapy
Research NewsGene therapy delivered by intravitreal injection
-
Research News
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
-
Researchers Identify Regions in the Retina to Target Therapies for Certain RP Patients
Research NewsUniversity of Pennsylvania investigators studied retinas of patients and canines with retinitis pigmentosa caused by mild mutations in RHO
-
In the Press
Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness
-
jCyte Reports Promising Results for Phase 2b Clinical Trial of its Cellular Therapy for RP
Research NewsThe emerging therapy is designed to work independent of the mutated gene causing vision loss
-
Accessibility
Zoom is a cloud-based video communications app that allows you to set up virtual video and audio conferencing, webinars, live chats, screen-sharing, and other collaborative capabilities.
-
AGTC Planning Phase 2/3 Clinical Trial for XLRP Gene Therapy
Research NewsThe company is also expanding its Phase ½ trial for the emerging treatment
